Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Avalon GloboCare ( (ALBT) ) is now available.
On August 28, 2025, Avalon GloboCare announced its plan to launch the KetoAir™ breathalyzer device in the UK starting September 1, 2025. This device, designed for ketogenic health management, measures breath acetone concentration and is compatible with Apple and Android devices. The launch aims to expand Avalon’s market presence amid the growing popularity of ketogenic diets in the UK, potentially enhancing the company’s industry positioning and offering stakeholders new opportunities in the health and wellness sector.
More about Avalon GloboCare
Avalon GloboCare Corp. is a developer of precision diagnostic consumer products and focuses on advancing intellectual property in cellular therapy. The company markets the KetoAir™ breathalyzer device, which is registered with the U.S. Food and Drug Administration as a Class I medical device, and plans to develop additional diagnostic uses for this technology. Avalon also owns and operates commercial real estate.
Average Trading Volume: 689,240
Technical Sentiment Signal: Sell
Current Market Cap: $8.05M
See more insights into ALBT stock on TipRanks’ Stock Analysis page.